JP2021525524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021525524A5 JP2021525524A5 JP2020566909A JP2020566909A JP2021525524A5 JP 2021525524 A5 JP2021525524 A5 JP 2021525524A5 JP 2020566909 A JP2020566909 A JP 2020566909A JP 2020566909 A JP2020566909 A JP 2020566909A JP 2021525524 A5 JP2021525524 A5 JP 2021525524A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cell
- chain variable
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135422A JP2024178156A (ja) | 2018-05-31 | 2024-08-14 | がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ－ｔ） |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678878P | 2018-05-31 | 2018-05-31 | |
| US62/678,878 | 2018-05-31 | ||
| US201962799513P | 2019-01-31 | 2019-01-31 | |
| US62/799,513 | 2019-01-31 | ||
| PCT/US2019/035010 WO2019232444A1 (en) | 2018-05-31 | 2019-05-31 | Chimeric antigen receptor t cells (car-t) for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135422A Division JP2024178156A (ja) | 2018-05-31 | 2024-08-14 | がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ－ｔ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525524A JP2021525524A (ja) | 2021-09-27 |
| JP2021525524A5 true JP2021525524A5 (enExample) | 2022-06-07 |
| JP7542854B2 JP7542854B2 (ja) | 2024-09-02 |
Family
ID=68697704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566909A Active JP7542854B2 (ja) | 2018-05-31 | 2019-05-31 | がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ－ｔ） |
| JP2024135422A Pending JP2024178156A (ja) | 2018-05-31 | 2024-08-14 | がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ－ｔ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135422A Pending JP2024178156A (ja) | 2018-05-31 | 2024-08-14 | がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ－ｔ） |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200071397A1 (enExample) |
| EP (1) | EP3802798A4 (enExample) |
| JP (2) | JP7542854B2 (enExample) |
| KR (1) | KR102921474B1 (enExample) |
| CN (1) | CN112912493A (enExample) |
| AU (2) | AU2019279021A1 (enExample) |
| CA (1) | CA3101505A1 (enExample) |
| IL (1) | IL279063B2 (enExample) |
| SG (1) | SG11202011383VA (enExample) |
| WO (1) | WO2019232444A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP3368571B1 (en) | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| EP4778585A2 (en) | 2019-05-07 | 2026-07-22 | Gracell Bioscience (Shanghai) Co., Ltd. | Engineered immune cell targeting bcma and use thereof |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| AU2020346887A1 (en) * | 2019-09-13 | 2022-04-07 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting CD371 and uses thereof |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| EP4211245A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
| WO2022093825A1 (en) * | 2020-10-26 | 2022-05-05 | Memorial Sloan-Kettering Cancer Center | Cells with cd70 knockout and uses for immunotherapy |
| WO2022098756A1 (en) * | 2020-11-03 | 2022-05-12 | WUGEN, Inc. | Chimeric antigen receptor cell therapy |
| US20240000838A1 (en) * | 2020-11-30 | 2024-01-04 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
| KR102824136B1 (ko) * | 2021-04-05 | 2025-06-25 | 주식회사 셀렌진 | Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN116179493A (zh) * | 2021-09-29 | 2023-05-30 | 成都美杰赛尔生物科技有限公司 | 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用 |
| TW202330594A (zh) * | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN114317607B (zh) * | 2021-12-31 | 2024-08-02 | 苏州桑尼赛尔生物医药有限公司 | 融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法 |
| CN114369622A (zh) * | 2021-12-31 | 2022-04-19 | 西安桑尼赛尔生物医药有限公司 | 同时靶向cd7和cd19的双特异通用型car-t细胞及其制备方法 |
| AU2023275671A1 (en) * | 2022-05-27 | 2024-11-14 | Kite Pharma, Inc. | Non-viral delivery of cell therapy constructs |
| WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
| CN116284435A (zh) * | 2022-09-19 | 2023-06-23 | 卡瑞济(北京)生命科技有限公司 | EGFRvIII嵌合抗原受体及其用途 |
| WO2024097797A1 (en) * | 2022-11-02 | 2024-05-10 | Medisix Therapeutics, Inc. | Blockade of cd3 expression and chimeric antigen receptors for immunotherapy |
| CN116514992B (zh) * | 2022-11-07 | 2024-05-24 | 武汉波睿达生物科技有限公司 | 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用 |
| KR20250088543A (ko) * | 2023-05-19 | 2025-06-17 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
| CN119269786A (zh) * | 2023-06-29 | 2025-01-07 | 上海细胞治疗集团股份有限公司 | 一种评估car产生细胞免疫应答的方法 |
| CN119548619A (zh) * | 2023-08-10 | 2025-03-04 | 亘喜生物科技（上海）有限公司 | 一种双靶点car-t细胞在治疗系统性红斑狼疮及其他b细胞自身免疫病中的用途 |
| CN121752724A (zh) * | 2023-08-30 | 2026-03-27 | 赋生元公司 | 在免疫检查点基因座处对表达嵌合抗原受体的免疫细胞进行工程化以用于疾病治疗的方法 |
| KR20250037240A (ko) | 2023-09-08 | 2025-03-17 | 김진호 | 자동반려견산책기 |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| CN117866110B (zh) * | 2023-12-27 | 2024-06-11 | 广东唯泰生物科技有限公司 | 一种靶向flt-3的第四代嵌合抗原受体及其应用 |
| CN120960406A (zh) * | 2024-05-16 | 2025-11-18 | 浙江大学 | 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用 |
| WO2026024685A1 (en) * | 2024-07-23 | 2026-01-29 | Feromics Inc. | Uses of immunomodulatory fusion proteins to enhance efficacy of car-expressing immune effector cells |
| CN119685260B (zh) * | 2024-12-17 | 2026-01-13 | 上海交通大学医学院附属瑞金医院 | 一种具有新型穿膜区的嵌合抗原受体t细胞及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051926A2 (en) * | 2001-12-14 | 2003-06-26 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| WO2005070120A2 (en) * | 2004-01-09 | 2005-08-04 | Serologicals Investment Company, Inc. | Cell culture media |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| KR102546296B1 (ko) * | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| US20180371052A1 (en) * | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| US12350349B2 (en) * | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| CN118581046A (zh) | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| JP2021525518A (ja) * | 2018-05-31 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 細胞をゲノム編集及び活性化するための方法 |
| US20200040056A1 (en) | 2018-05-31 | 2020-02-06 | Washington University | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies |
| CN112533942A (zh) * | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
-
2019
- 2019-05-31 IL IL279063A patent/IL279063B2/en unknown
- 2019-05-31 US US16/428,624 patent/US20200071397A1/en not_active Abandoned
- 2019-05-31 AU AU2019279021A patent/AU2019279021A1/en not_active Abandoned
- 2019-05-31 CN CN201980050879.1A patent/CN112912493A/zh active Pending
- 2019-05-31 JP JP2020566909A patent/JP7542854B2/ja active Active
- 2019-05-31 SG SG11202011383VA patent/SG11202011383VA/en unknown
- 2019-05-31 CA CA3101505A patent/CA3101505A1/en active Pending
- 2019-05-31 EP EP19811980.2A patent/EP3802798A4/en active Pending
- 2019-05-31 KR KR1020207037911A patent/KR102921474B1/ko active Active
- 2019-05-31 WO PCT/US2019/035010 patent/WO2019232444A1/en not_active Ceased
-
2024
- 2024-06-28 US US18/759,025 patent/US20250101099A1/en active Pending
- 2024-08-14 JP JP2024135422A patent/JP2024178156A/ja active Pending
-
2025
- 2025-11-14 AU AU2025267444A patent/AU2025267444A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7514746B2 (ja) | 細胞 | |
| JP2022516389A5 (enExample) | ||
| JP7733051B2 (ja) | キメラ抗原受容体 | |
| JP2021525518A5 (enExample) | ||
| JP2024522357A (ja) | クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| JP2023178386A (ja) | 細胞 | |
| CN107735407A (zh) | 治疗剂 | |
| JP2019537433A5 (enExample) | ||
| TW201904997A (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| JP2022516557A5 (enExample) | ||
| CN107406517A (zh) | 包含cd19结合域的嵌合抗原受体(car) | |
| CN110741018A (zh) | 抗原结合结构域 | |
| JP2017500869A5 (enExample) | ||
| RU2015144332A (ru) | Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора | |
| JP2022512882A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| JP2020537521A (ja) | 細胞 | |
| CN112118892A (zh) | Cd79特异性嵌合抗原受体 | |
| US20190038730A1 (en) | Engineered cells & methods | |
| Qian et al. | The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing | |
| CA3159808A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| JP2022513372A5 (enExample) | ||
| JP2023548974A (ja) | Ｔ細胞抗原カプラを含む細胞及びその使用 |